Literature DB >> 14980267

Pathogenesis of respiratory syncytial virus bronchiolitis-related wheezing.

Stelios Psarras1, Nikolaos G Papadopoulos, Sebastian L Johnston.   

Abstract

Respiratory syncytial virus (RSV) is a common cause of virus infection of the human respiratory tract during the first two years of life, with virtually all children experiencing at least one infection within this period. Although this usually leads to mild respiratory illness, some infants develop more severe disease (bronchiolitis, pneumonia, etc.) affecting the lower airways and frequently requiring hospitalisation. There is evidence that bronchiolitis hospitalisations have increased during the last two decades and many of the hospitalised children develop wheezing later in life. The immune response to the virus is probably a major factor in the development or the expression of the pathological phenotype. In particular, a bias towards type-2 cytokine responses seems to be associated with more severe disease, whereas a type-1 response leads to more effective viral clearance and milder illness. Although the virus by itself triggers a type-1 response, a preexisting type-1 deficiency may contribute to the severity of the disease. In that sense, RSV bronchiolitis may serve as a marker, reflecting predisposition of the individual for virus induced wheezing early in life and/or asthma later in life.

Entities:  

Mesh:

Year:  2004        PMID: 14980267     DOI: 10.1016/s1526-0542(04)90034-6

Source DB:  PubMed          Journal:  Paediatr Respir Rev        ISSN: 1526-0542            Impact factor:   2.726


  18 in total

1.  Influenza A virus among the hospitalized young children with acute respiratory infection. Is influenza A co infected with respiratory syncytial virus?

Authors:  Seyed Mohammad Alavi; Manoochehr Makvandi; Saied Najafi-Fard; Leila Alavi
Journal:  Caspian J Intern Med       Date:  2012

Review 2.  Heterogeneity and the origins of asthma.

Authors:  Rebecca Scherzer; Mitchell H Grayson
Journal:  Ann Allergy Asthma Immunol       Date:  2018-06-19       Impact factor: 6.347

3.  Respiratory syncytial virus infection reduces beta2-adrenergic responses in human airway smooth muscle.

Authors:  Paul E Moore; Gary Cunningham; Mark M Calder; Anthony D DeMatteo; Mark E Peeples; Marshall L Summar; R Stokes Peebles
Journal:  Am J Respir Cell Mol Biol       Date:  2006-06-08       Impact factor: 6.914

Review 4.  Reading the viral signature by Toll-like receptors and other pattern recognition receptors.

Authors:  Trine H Mogensen; Søren R Paludan
Journal:  J Mol Med (Berl)       Date:  2005-01-06       Impact factor: 4.599

Review 5.  Understanding the mechanisms of viral induced asthma: new therapeutic directions.

Authors:  Nicole G Hansbro; Jay C Horvat; Peter A Wark; Philip M Hansbro
Journal:  Pharmacol Ther       Date:  2008-01-29       Impact factor: 12.310

6.  Thymic stromal lymphopoietin is induced by respiratory syncytial virus-infected airway epithelial cells and promotes a type 2 response to infection.

Authors:  Hai-Chon Lee; Mark B Headley; Yueh-Ming Loo; Aaron Berlin; Michael Gale; Jason S Debley; Nicholas W Lukacs; Steven F Ziegler
Journal:  J Allergy Clin Immunol       Date:  2012-09-13       Impact factor: 10.793

7.  RNA interference-mediated silencing of the respiratory syncytial virus nucleocapsid defines a potent antiviral strategy.

Authors:  Rene Alvarez; Sayda Elbashir; Todd Borland; Ivanka Toudjarska; Philipp Hadwiger; Mathias John; Ingo Roehl; Svetlana Shulga Morskaya; Rick Martinello; Jeffrey Kahn; Mark Van Ranst; Ralph A Tripp; John P DeVincenzo; Rajendra Pandey; Martin Maier; Lubomir Nechev; Muthiah Manoharan; Victor Kotelianski; Rachel Meyers
Journal:  Antimicrob Agents Chemother       Date:  2009-06-08       Impact factor: 5.191

8.  NGF is an essential survival factor for bronchial epithelial cells during respiratory syncytial virus infection.

Authors:  Sreekumar Othumpangat; Laura F Gibson; Lennie Samsell; Giovanni Piedimonte
Journal:  PLoS One       Date:  2009-07-31       Impact factor: 3.240

9.  A disease model for wheezing disorders in preschool children based on clinicians' perceptions.

Authors:  Ben D Spycher; Michael Silverman; Juerg Barben; Ernst Eber; Stéphane Guinand; Mark L Levy; Caroline Pao; Willem M van Aalderen; Onno C P van Schayck; Claudia E Kuehni
Journal:  PLoS One       Date:  2009-12-31       Impact factor: 3.240

10.  Review of palivizumab in the prophylaxis of respiratory syncytial virus (RSV) in high-risk infants.

Authors:  Asunción Mejías; Octavio Ramilo
Journal:  Biologics       Date:  2008-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.